Takeda Pharmaceutical Co ADR (NYSE: TAK) is -5.19% lower on its value in year-to-date trading and has touched a low of $12.57 and a high of $15.08 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TAK stock was last observed hovering at around $13.62 in the last trading session, with the day’s loss setting it -0.09%.
Currently trading at $13.53, the stock is -1.87% and -4.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.79 million and changing -0.66% at the moment leaves the stock -2.69% off its SMA200. TAK registered -1.38% loss for a year compared to 6-month gain of 1.88%. The firm has a 50-day simple moving average (SMA 50) of $14.2446 and a 200-day simple moving average (SMA200) of $13.90805.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -5.58% loss in the last 1 month and extending the period to 3 months gives it a -8.33%, and is -0.88% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.16% over the week and 1.11% over the month.
Takeda Pharmaceutical Co ADR (TAK) has around 49281 employees, a market worth around $42.90B and $30.22B in sales. Current P/E ratio is 22.44 and Fwd P/E is 29.75. Profit margin for the company is 6.36%. Distance from 52-week low is 7.59% and -10.28% from its 52-week high. The company has generated returns on investments over the last 12 months (2.42%).
with sales reaching $1.13T over the same period.The EPS is expected to shrink by -13.98% this year, but quarterly earnings will post 643.96% year-over-year. Quarterly sales are estimated to grow 1.86% in year-over-year returns.
Takeda Pharmaceutical Co ADR (TAK) Top Institutional Holders
359.0 institutions hold shares in Takeda Pharmaceutical Co ADR (TAK), with institutional investors hold 2.45% of the company’s shares. The shares outstanding are 3.17B, and float is at 3.17B with Short Float at 0.19%. Institutions hold 2.45% of the Float.
The top institutional shareholder in the company is CAPITAL RESEARCH GLOBAL INVESTORS with over 13.13 million shares valued at $169.86 million. The investor’s holdings represent 0.8366% of the TAK Shares outstanding. As of 2024-06-30, the second largest holder is MONDRIAN INVESTMENT PARTNERS LTD with 7.74 million shares valued at $108.34 million to account for 0.4932 of the shares outstanding. The other top investors are MORGAN STANLEY which holds 4.99 million shares representing 0.3178% and valued at over $64.53 million, while MILLENNIUM MANAGEMENT LLC holds 0.277 of the shares totaling 4.35 million with a market value of $56.24 million.
Takeda Pharmaceutical Co ADR (TAK) Insider Activity
#####
Takeda Pharmaceutical Co ADR disclosed in a document filed with the SEC on Jan 24 ’24 that TAKEDA PHARMACEUTICAL CO LTD (10% Owner) sold a total of 3,703,703 shares of the company’s common stock. The trade occurred on Jan 24 ’24 and was made at $8.10 per share for $30.0 million. Following the transaction, the insider now directly holds 3.76 million shares of the TAK stock.
